Most people have heard recent news reports regarding a Salmonella outbreak caused by peanut butter now being sold in Trader Joe's stores throughout the nation and even right here in Bergen County. The supermarket chain has ordered a voluntary recall of the tainted peanut butter as a precautionary measure.
About two years ago, New Jersey company Johnson & Johnson made the widely-publicized decision to recall the ASR artificial hip manufactured and sold by DePuy Orthopaedics, a unit of J&J. The company set aside $3 billion to compensate people who had filed personal injury lawsuits in connection with the defective products, and seemed to acknowledge the danger of metal-on-metal artificial hips.
Last month, the U.S. Food and Drug Administration (FDA) proposed a policy which, if adopted, could significantly increase the oversight and safety of the medical device industry. Under the proposal, each individual device would receive its own identification number, allowing medical professionals and manufacturers to better track defective products, determine the cause of the problems and alert other patients who are using the same device.
Earlier this week, a unit of New Jersey-based Johnson & Johnson announced that it planned to discontinue sales of its vaginal mesh implants. The company denies that the decision was made in response to the product liability lawsuits that have been filed in connection with the mesh, but that the "negative overall publicity about vaginal mesh devices" motivated the discontinuation.
Earlier this week, we began a look at common issues with the FDA's approval process which have resulted in unsafe medical devices being approved for sale and use by patients in New Jersey and throughout the country and world. As a result, many patients who have received these medical products have reported adverse side effects including debilitating pain, injury and even death.
Slow and steady seems to be the name of the game in the main personal injury lawsuit against DePuy Orthopaedics, a division of New Jersey company Johnson & Johnson, over its faulty artificial hip replacement products.
According to a recently released document, New Jersey company Johnson & Johnson began taking action to phase out the use of its metal-on-metal artificial hips just weeks after the receiving a letter from U.S. Food and Drug Administration. In that letter, the agency reportedly turned down Johnson's application to sell the medical product in the United States, and told the company to submit additional safety data if it wanted to pursue the application.
After a string of product recalls and products liability lawsuits, the chief executive officer of Johnson & Johnson is reportedly stepping down from his position later this spring. Although the New Jersey company's revenue has doubled in the past decade, the many product recalls in recent years have reportedly cost Johnson & Johnson more than $1 billion, as well as the serious hits to its public image and consumers' trust.
Last week, we wrote that the U.S. Food and Drug Administration had ordered additional research into the vaginal mesh products that have caused injury and even death to women throughout the country.
Earlier this week, we wrote about the recent influx of product liability lawsuits against New Jersey-based Johnson & Johnson regarding its vaginal mesh implant products, which have resulted in injury and death in hundreds of women throughout the country. The vaginal mesh suits are not the only litigation facing Johnson & Johnson at this time. The company is also defending itself against a growing class action products liability lawsuit after "mechanical failure" forced the recall of hundreds of artificial joints.